Results 151 to 160 of about 17,208,238 (361)

Computational-based drug design of novel small molecules targeting p53-MDMX interaction

, 2023
Abel U. Egbemhenghe, Olajide Enoch Aderemi, Bamidele Samson Omotara, Faith Iyayi Akhimien, Faith Osaretin Osabuohien, Habeebulah Ajibola Adedapo, Oluwakemi Rita Temionu, Winner Amaka Egejuru, Chinedum Favour Ajala, Meejay Francis Ihunanya, Oluwatosin Oluwafunmilola Oluwafemi, Chinyere Felicia Duncan Onu, Abosede Christiana Ajibare, Christopher Ddamulira, Justin Onyekachukwu Abalum, Olanrewaju Michael Afolayan   +15 more
openalex   +2 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Do We Build Similar Molecules for Comorbid Diseases? Tevarud in Drug Design, an Analysis for Depression and Inflammation

, 2020
F. Esra Önen Bayram, Sarah A. A. Alradhwani, Gulcin Tugcu, Hande Si̇pahi̇   +3 more
openalex   +2 more sources

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Benchmarking Molecular Mutation Operators for Evolutionary Drug Design. [PDF]

Int J Mol Sci
Acosta Murillo R, Zapata-Morin PA, Ortiz-Bayliss JC.   +2 more
europepmc   +1 more source

Advancements in Drug Analysis through Nanoscale Sensors: A Study on Production, Design and Applications of Nanosensors and Nano-Biosensors

Palwasha Tehseen
openalex   +1 more source

A UML-based object-oriented approach for design and simulation of a drug delivery system

, 2008
Qifeng Cui, Xuan F. Zha, Chengliang Liu, Wen Feng Lu   +3 more
openalex   +2 more sources

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source

COMPUTER AIDED DRUG DESIGN: A MINI-REVIEW

, 2020
Aateka Y Barrawaz
openalex   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source